I think this is the sort of issue which we could debate because it is not solidly evidence-based so I would welcome a diversity of opinions on this issue. In my own practice, I am looking closely at any patient who has been on nilotinib for more than 5 years and reviewing the risk-benefit balance of continuing versus either reducing dose or switching to imatinib (assuming that is a reasonable option for that patient). This is probably less controversial if the patient is in a DMR but has no interest in TFR where the benefits of continuing nilotinib long term are quite limited and the risks, at least in some cases, are considerable. The situation is probably similar for patients on long term dasatinib, although in this case we don’t have the 10 year vascular event data that we have for nilotinib, so the risk side of the equation is less certain.